Cognition Therapeutics, Inc.
NCM: CGTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Cognition Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CGTX Z-Score →About Cognition Therapeutics, Inc.
Healthcare
Biotechnology
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
📊 Fundamental Analysis
Cognition Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -88.6%, which indicates that capital utilization is currently under pressure.
At a current price of $0.90, CGTX currently trades near the bottom of its 52-week range (19%), indicating potential value or weakness (Range: $0.22 - $3.83).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$80.83M
Trailing P/E
--
Forward P/E
-3.02
Beta (5Y)
1.40
52W High
$3.83
52W Low
$0.22
Avg Volume
1.05M
Day High
Day Low